No abstract available.
Drug Therapy* ; Ovarian Neoplasms*

No abstract available.
Drug Therapy* ; Ovarian Neoplasms*

No abstract available.
Cisplatin* ; Drug Therapy* ; Ovarian Neoplasms*

No abstract available.
Cisplatin* ; Drug Therapy* ; Ovarian Neoplasms*

Cerebral metastses secondary to primary epithelial ovarian carcinoma are unusual. The incidence was estimated under 1%, but some authors reported higher incidence than previously reported data. Recently, we experienced a case of cerebral metastasis secondary to primary epithelial ovarian cancer. We present this case with review of brief related literatures.
Drug Therapy* ; Incidence ; Neoplasm Metastasis ; Ovarian Neoplasms

No abstract available.
Carboplatin* ; Drug Therapy* ; Ovarian Neoplasms* ; Paclitaxel*

No abstract available
Cell Line* ; Drug Therapy ; Humans* ; Ovarian Neoplasms*

No abstract available.
Drug Therapy ; Japan ; Joints ; Ovarian Neoplasms

Surgery continues to be an important option in the management of recurrent gynecologic malignancies. As a single modality, it can be the sole curative treatment for a selected group of patients with localized recurrent malignancy and contributes to the management of patients with more disseminated recurrent malignancy as part of multimodal treatment. The use of exenterative surgery for localized recurrence has been extended, and complications have been minimized. Our understanding of the role of cytoreduction in disseminated recurrence has increased, but care must be taken in order to maximize the benefit of cytoreduction and minimize morbidity until the evidences are more clarified in prospective randomized trial. Morbidity related to radical surgery can be reduced without compromising patient cure by individualizing surgery. Moreover, newer reconstructive techniques can improve quality of life. Sometimes, surgery can be performed with relatively simple procedures, such as wide local excision. However, for more disseminated cancers, such as metastatic ovarian cancer, surgery can be very complex, requiring resection of several non-gynecological organs. Therefore extensive surgical training and experience is needed to successfully manage patients with these challenging conditions, and this has resulted in the development of the subspecialty of gynecological oncology. A brief update on the role of surgery in the management of recurrent gynecologic malignancies is presented in this article.
Combined Modality Therapy ; Humans ; Ovarian Neoplasms ; Quality of Life ; Recurrence

OBJECTIVE: The chemotherapy response score (CRS) system based on histopathological examination has been recently proposed for tubo-ovarian high-grade serous carcinoma (HGSC) to assess response to neoadjuvant chemotherapy (NAC). This study was aimed at validating the CRS system in an external cohort of tubo-ovarian HGSC patients. METHODS: This study included 110 tubo-ovarian HGSC patients who underwent NAC followed by interval debulking surgery. The 3-tiered CRS of the omental and adnexal tissue sections was determined by 3 independent pathologists. Differences in patient outcomes according to CRS were analyzed. RESULTS: The CRS system was highly reproducible among the 3 pathologists. Fleiss' kappa value and Kendall's coefficient of concordance for the omental CRS were 0.656 and 0.669, respectively. The omental CRS significantly predicted progression-free survival (PFS). The median PFS of patients whose tumors exhibited the omental CRS 1–2 (15 months) was significantly shorter than that of patients with an omental CRS of 3 (19 months; p=0.016). In addition, after adjusting for age, stage, and debulking status, the omental CRS was an independent prognostic factor for PFS of tubo-ovarian HGSC patients who were treated with NAC (adjusted hazard ratio [HR]=1.74; 95% confidence interval [CI]=1.05–2.87). CONCLUSION: The CRS system for assessing NAC response was a reproducible prognostic tool in our cohort. The application of the CRS system after NAC can improve survival estimation in HGSC patients.
Cohort Studies ; Disease-Free Survival ; Drug Therapy* ; Humans ; Ovarian Neoplasms